Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.

This review discusses the development and potential therapeutic effects of nitroxide small molecule agents for age-related macular degeneration and cardiovascular disease, but reports no new clinical results.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.

This review discusses the potential of using triads of repositioned medicines targeting multiple pathogenic mechanisms to prevent or delay retina degeneration, but reports no new results.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study highlights the need for further research on dysregulated immune and fibrotic pathways in morphea to better understand its pathogenesis and develop new biomarkers and therapies.

This review discusses various herbal and pharmaceutical products, including their purported uses and possible interactions, but reports no new research findings.

This study surveyed patients with idiopathic inflammatory myopathy and found that glucocorticoid treatment commonly leads to adverse effects, particularly sleep disturbance, mood swings, and weight gain, with more severe effects reported by female patients.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study observed that morbilliform rash was the most common adverse cutaneous drug reaction, and antimicrobials, particularly nevirapine, were the primary causative agents among patients in Rajkot, Gujarat.

This case report describes the first documented occurrence of hemi-Isaac's syndrome or acquired neuromyotonia affecting only one side of the body, with symptoms improving after immunomodulatory treatment.

A document listed serious side effects from various drugs, including deaths and diseases, emphasizing the importance of being aware of drug side effects.

This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

This study found that systemic administration of NDP-MSH, a melanocortin receptor agonist, provided neuroprotective effects on dopaminergic nigrostriatal neurons in a mouse model of Parkinson's disease, reducing neuroinflammation and suggesting a role for regulatory T cells in these neuroprotective effects.

In their 1957 study, Neuman and Neuman suggested that magnesium deficiency may inhibit the ion exchange process required for calcium ions to enter extracellular fluid, potentially affecting calcium mobilization.

This study found that stilbamidine and hydroxystilbamidine can inhibit the release of specific enzymes from lysosomes and mitochondria in rabbit liver at certain concentrations, with effects similar to cortisol and chloroquine.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

Resident memory T cells and necroptosis may drive fibrosis in eosinophilic fasciitis and morphea.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This study found that midazolam improved PTSD-associated behavioral deficits in rats through its action on the TSPO, CBR, and neurosteroidogenesis pathways.

This study found that SMR-2 and SMR-6, analogs of retinoic acid and retinol, were approximately 100 times more toxic than retinoic acid in mice, inducing hypervitaminosis A and affecting various organs and tissues.

This research observed that Moracin M, a compound from the Moraceae family, significantly promotes hair growth and angiogenesis via the Wnt signaling pathway in human dermal papilla cells, offering a promising alternative to current hair growth treatments like minoxidil.